Literature DB >> 36128264

Demand-side Interventions to Control Moral Hazard in Health Systems, Beneficial or Detrimental: A Systematic Review Study.

Zohreh Koohi Rostamkalaee1, Mehdi Jafari1, Hasan Abolghasem Gorji2.   

Abstract

Background: Moral hazard is one of the main reasons for health market failure where supply-side and demand-side interventions are used for its control and prevention. This study aimed to identify the effects of demand-side interventions on moral hazards in health systems.
Methods: For this systematic review, electronic databases, including Scopus, PubMed, Web of Science, Embase, ProQuest, Google Scholar's search engine, and Iranian databases such as SID and Magiran, were investigated. No time limitation was considered in the search process. The narrative synthesis approach was used for data analysis.
Results: Out of 7484 retrieved papers, 61 papers were included in the study. The Identified effects were divided into 2 categories: health services consumption effects and financial effects, which were summarized in the form of advantages and disadvantages. The most important advantages included a decrease in the utilization of different services and a reduction in health expenditures. Also, the most important disadvantages included lower quality of care, shifting financing burden to the consumers, and limited access to necessary care.
Conclusion: The results showed that the most benefits of interventions, especially in cost-sharing and waiting list interventions, are for insurance organizations, where the disadvantages also affect consumers more. Therefore, it is necessary to pay more attention to these effects and their management because a lack of attention in this regard may impair the performance of insurance financial protection and health provision as one of the major goals of the health system.
© 2022 Iran University of Medical Sciences.

Entities:  

Keywords:  Demand-Side Intervention; Health Systems; Moral Hazards

Year:  2022        PMID: 36128264      PMCID: PMC9448464          DOI: 10.47176/mjiri.36.69

Source DB:  PubMed          Journal:  Med J Islam Repub Iran        ISSN: 1016-1430


Moral hazard is one of the health market concerns that affect both the provider and the consumer of health services, and its control methods are classified into supply-side and demand-side interventions. The effects of demand-side interventions are presented in this work as 2 general effects: health-care consumption effects and financial effects, which are summarized as advantages and disadvantages for each intervention.

Introduction

The uncertainty feature of health care makes the time of need for health services and their costs unpredictable (1). Insurance coverage is a solution to the uncertainty of health care(2) and fair financing of health services(3). Experts believe that insurance coverage distorts the patients’ choices and creates a problem known as a moral hazard(4). Moral hazardis a situation in which the consumer demands additional healthservices because of the insurance coverageand reduction in the price of health care (5). Moral hazardas a topic in the fie ld of behavioral economics in addition to changes in consumption behavior—leads to a reduction in preventive behaviors because of the reduced financial cost of health consequences. Insurance coverage also changes the behavior of the provider so that the provider also has no incentive to provide the optimal service and creates an induced demand for the patient to increase her income and benefits;(6) therefore, it is known as the consumer moral hazardand providermoral hazard(7). Moral hazard is one of the main reasons for the failure of the healthmarket(8). Reduction in welfare, reduction in insurance coverage, and increase in health costs are the negative consequences of moral hazard (9). Evidence shows that health care costs have increased in recent years(10,11). The increase in health spending was equivalent to 9% of Gross Domestic Product (GDP) in the Organization for Economic Co-operation and Development countries in 2018 and 18% of GDP in the United States in 2015. Moral hazard is recognized as one of the main factors in increasing the cost of health(12). Some interventions have been proposed to manage and reduce moral hazards. These interventions are divided into 2 categories: (1) supply-side interventions and (2) demand-side interventions. Supply-side interventions are used to control provider moral hazards, and demand-side interventions are used to control consumer moral hazards (7).Referral system and gate-keeping, managed care, payment systems such as diagnosis-related group per capita payment and global payment, consumption pattern review, statistical reports, and prospective consumption monitoring are the most common interventions to prevent and control moral hazards in supply-side (13,14). The most important demand-side interventions include cost-sharing, medical savings accounts (MSA)or health savings accounts (HSA), waiting lists, and nonuse incentives schemes(7). Cost-sharing is a method whose aim is to increase the responsibility of individuals by participating in the payment of health costs through out-of-pocket payments(15). Cost-sharing is determined in different ways, such as deductibles, coinsurance, copayment, and ceiling (16). Cost-sharing, while reducing the consumption of health services, can reduce insurance costs by preventing moral hazards. This method is common in countries with social health insurance(17). Medical savings accounts are kinds of personal accounts in which enrollees save a portion of their income to pay for health expenses. Health saving accounts are a financing tool, which is also used to control the consumer moral hazard (18). The waiting list is a method that rations health care according to the waiting time (19). The waiting list, by imposing the cost of time instead of paying directly, will reduce moral hazard(13). Nonuse incentive schemes encourage low consumption or nonconsumption in exchange for a lower premium (13)or generous coverage in the next contract (20). The premium reduction is often used to risk adjustment schemes (21). Since the implementation of any intervention requires the identification of possible consequences for planning to be dealt with, this study aimed to identifythe effects of demand-side interventions to control the moral hazard. Our focus in this study is on studies that have sought to reduce consumer moral hazard and used demand-side interventions in this regard. The results of this study are expected to be useful in reducing moral hazards planning and ultimately reducing health costs.

Methods

Data Sources and Searches Strategy

In this systematic review, the following electronic databases were searched until February 7, 2021: Scopus, PubMed, ISI Web of Science, Embase, ProQuest, and Iranian databases including SID and Magiran. Google Scholar’s search engine was used to ensure that all relevant records were covered. No time limitation was considered in the search process. On January 15, 2022, the databases indicated were searched to ensure that the most recent relatedstudies were not missed. During the new search, several studies were added. The main keywords used for searching databases included “moral hazard”, “principal agency problem”, “principal-agent dilemma”, “principal-agent problem”, “unnecessary use”, “unnecessary utilization”, “non-essential use”, “non-essential utilization”, “overutilization”, “health”, “health system”, “health insurance”, “health care”, “healthcare”, “health service”, “medical care”, and “medical service” (Appendix 1).

Inclusion and Exclusion Criteria

All Persian and English papers that examined the effect of demand-side interventions on controlling moral hazard or consumer moral hazard in health systems were included in this study. Papers without full texts, letters to editors, books, reports, seminars, and conference presentations were excluded.

Screening and Study Selection

Founded records were imported to the Endnote software Version 9. After removing duplicate papers, 2 skilled researchers independently conducted an initial screening of the records’ titles. In the second step, theabstracts of the remaining papers were screened independently by 2 researchers, and unrelated papers were removed. In the final screening round, the full texts of papers were independently assessed for inclusion and exclusion criteria by 2 authors. Any disagreement between the researchers was resolved by consultation with a third reviewer. Also, references of the selected papers were assessed to find additional papers. The literature selection and retrieval flow diagram are shown in Figure 1.
Fig. 1
Literature selection and retrieval flow diagram

Data Extraction and Quality Assessment

Data extraction was performed based on the following information: author (s), year of publication, country,study language, title, study design, demand-side intervention, analyzed outcome, main results, and quality appraisal score. Quality appraisal of the papers was performed using the Dixon-Woods quality appraisal checklist (22). The general characteristics of the included studies are presented in Appendix 2.

Data Analysis

The narrative synthesis approach was used to summarize the results of the studies because the studies were heterogeneous in terms of the type of study, lent of study, type of demand-side interventions and how to implement them, outcome variables, and high diversity in the approach of analyzing and reporting results. Thus, it was not possible to select a common criterion for the relationship between studies for meta-analysis. Hence, the findings are synthesized in text and table format to provide a summary of the effects and consequences of demand-side interventions.

Results

In the search of databases (N = 7468) and other sources (N = 16), a total of 7484 records were found after removing duplicate records and reviewing the inclusion and exclusion criteria during the screening steps of titles, abstracts, and reviewing the full text of selected papers. A total of 61 papers were included in the study (Fig. 1). The time of publication of the articles are from 1995 to 2000 (N = 1), from 2001 to 2005 (N = 9), from 2006 to 2010 (N = 10), from 2011 to 2015 (N = 17), as well as 24 studies from 2016 to 2021. Most studies were conducted in a quantitative approach (N = 44), but they were also in a qualitative approach (N = 2), review approach (N = 4), and theoretical approach based on the model formulation (N = 11). Demand-side interventions in these studies included cost-sharing (N = 47), medical or health savings accounts (N = 4), waiting lists (N = 4), and nonuse incentives (N = 6). The main findings of the study on the effects of demand-side interventions were presented in Table 1. The identified effects of the study were divided into 2 general effects: (1) health services consumption effects and (2) financial effectsfor each intervention. Health services consumption effects show the effect of interventions on outcomes such as demand and utilization of various health services, access to health services, and issues related to the quality of health services. Financial effects also show the effect of interventions on the expenditure of different health services, financial effects for consumers, and insurance organizations or other third-party payers.
Table 1

The Main Effects of Demand Side Interventions

Demand-side interventionHealth services consumption effectsFinancial effects
Cost-sharing - Deductibles reduce the consumption of different services (16) - Copayments decrease the utilization of ambulatory services (23-31) and prescriptionsdrug (25,32)- Reduction in unnecessary emergency room visits in copayments plan (33-35) - Transitory negative effects of copayments on the frequency of physician visits (36)- Negative relationship between moral hazards and coinsurance (9)- Reduction in elective and preventive services with higher cost-sharing (37)- Correlation between the deductible rate and health care utilization (38) - No effect on the primary care physician visits (39-41) and hospitalization in copayments plan (25,29) - Copayments do not affect the nonemergency visits in emergency departments (42) - No deterrent effects for seeking the healthcare in vulnerable groups in copayments (26,41) - The substitution effects from services need cost-sharing to free services or with less out-of-pocket payment(25,27,43)- Increasing hospitalization with copayments (16,24) - limited or negativeeffect on accessto long term care (44)- Reduction in utilization of both efficient and inefficient care (21,45)- Limiting access to health services (21)- More sensitivity of low-income patients for health care utilization (25,26,28)- Less sensitivity of inpatient service users to cost-sharing than that of clinic users (46)- Inducing inequitable service utilization (46)- Reduction in ambulatory services in voluntary deductible(5) and HDHPS (45,47)- Higher deductibles reducing deferred care (48)- Correlation between the HDHPS and lower smoking (49)- Moderate reduction in-office visits and general laboratory tests among the HDHPs enrollees (50)- No differences in visit rates for acute conditions and radiology tests among the HDHPs enrollees (50)- No significant effect of the variable deductible on utilization (51)- Positive effect of the voluntary deductible on the number of spending in the hospital (5)- Little effect of the average income-based deductible on access to medications and other health services (52)- Increase in demand for specialist visits, diagnostic tests,s and medication utilization with cost-sharing exemption (53)- Reduction in use of preventive care among the HDHPs enrollees (45,47,54) - Existence of intertemporal substitutioneffects in the HDHPs enrollees (55)- Reduction in medication adherence among the HDHPs enrollees (45)- More delayed care in vulnerable groupsin higher deductible plans (48)- Omitting needed the care to save money among the HDHPs enrollees (45)- Increasing medication adherence among the VBID brand statin users (56) - Decreasing effect ofcopaymentson pharmaceutical expenditure (32) - Negative and retained effects of copaymentson visit expenditures (36)- Increase in profit of insurance companiesdue to reduced consumer financial claims in deductible plan (16) - Slight decrease in expenditure (12)- Increasing cost-containment incentives with thedeductible amounts (57)- Positive effect on the efficiencyof long-term care (44) - Modest efficiency gain in uniform copayments (27)- Higher reduction of ex-post moral hazard in copayments with the premium reduction frame (58)- Increasing financing burdens on deductibles plans (16) - Shifting the financing burden to the consumers in copayments plans (25)- Deductible is not an optimal solution because of itsadverse effects (21,43) - Increasing the effect of copayments on medical costs because of increasing inpatient servicesand substitution effects (24)- Small price sensitivity for the GPs visit in acute conditions and strong sensitivity in chronic conditions to thecopayments (31)- leading to inefficient care (21)- lower health care expenditure in the HDHPs and CDHPs (45,54,59)- Decreasing the effect of higher deductible plans on medical debt (48)- lower out-of-pocket expenditures in shifted deductibles (60) - Improving the healthcare price transparency in the CDHPs (59)- Safe reduction of public spending on medicine in some groups in average income-based deductibles (52)- Optional deductibles are compatible with the principles of solidarity (61)- Voluntary deductibles reduce insurance claims (moral hazard) (61) - Higher spending in the free care plan at the beginning of a coverage year and higher spending inhigh deductible plans at the end of a coverage year (55) - More medical debts for vulnerable groups in higher deductible plans (48)- Healthy people, men, and highly educated ones are more likely to have a voluntary deductible (5,62)- Tiers cost-sharing is effective for demanding low-priced drugs (63)- Treatment-specific copayments cause reductions in moral hazard (64)- Differential cost-sharing based on the disease status is the optimal health insurance(65)- Value-based cost-sharing is the optimal health insurance (66)
Medical Saving Accounts )MSA/ ( Health Saving Accounts) HSA/( - Negative relationship withoutpatient utilization (18)- Suitable for enabling consumption(18)- Negative effect on reducing moral hazard(67) - Restrictions on the use of funds (67)- Increasing individual savings or preventive behavior (68)- Reducing members’ health costs due to reduced MSA funds (69)- Being useful to reduce costs and save for the future (18)- Having a negative effect on containing medical expenses. (67) - Having a positive effect on medical expenses for healthier groups (67)- Reducing savings in health accounts despite generous employers in voluntary design (54)
Waiting time - Lower optimal quality of health care (70)- Reduction in the public sectors’ incentive to reduce waiting time by the presence of private sectors (71) - Patients’ willingness to pay for a reduction in waiting time(70)- No optimal design (19,70,72)- No welfare gain (70)- potentially encouraging high-income patients or patients with high waiting costs to select private settings (72)
Non-use incentives - Increasing Risk reduction behavior and improving the utility of insured people (20)- Reduction in the likelihood of visiting GPs (73)- Reduction of moral hazard (73) - Limited effect of extensive risk adjustment on access to long term care (44)- No restriction on consumption of efficient care(21) - Less optimistic and less justified compared to cost-sharing. (74) - Limited effect on the efficiency of long-term care (44)- Reduction in the cost of general practitioner visits (73)- Lower social costs with a smaller patient risk premium than the price of provider information (75)

* High deductible health plans (HDHPS), **consumer-directed health plans (CDHPs), ***Value-based Insurance Design (VBID, ****GPs: general practitioners

Table 2 shows the most important advantages and disadvantages of demand-side interventions.
Table 2

The Most Important Advantages and Disadvantages of Demand Side Interventions

Demand-side interventionAdvantagesDisadvantages
Cost-sharing - Decrease in the utilization of different services, especially ambulatory services (5,16,23-35,37,45,47,54)- Having lower health care expenditure (32,36,45,52,54,59-61,63,64)- Increasing profits of third-party payers due to reduced consumer financial claims (16)- Improving healthcare price transparency in CDHPs (59) - Lower quality of care because of: o More hospitalization due to substitution effects (16,24) o Decreasing the utilization of both efficient and inefficient care (preventive care, medication adherence,) (21,45,47,54)- limiting access to necessary health services with increased cost-sharing (21,44,45)- Shifting financing burden to the consumers (16,25)- Increasing total medical costs because of substitution effect from cares with cost-sharing to free or less out-of-pocket care (24,25,27,43)- More sensitivity of low-income patients (25,26,28,48)
Medical Savings Accounts (MSA)/ Health Savings Accounts (HSA/( - Being suitable for enabling consumption (18)- Increasing savings for the future (18,68)- Reduction in health expenditures (18,69) - Restrictions on the use of funds (67)
Waiting time - Reduction in public health costs because of shifting high-income and high-waiting costs of consumers to the private sector (71,72) - lower quality of care (70)- patients’ willingness to pay for a reduction in waiting time (70)- No welfare gains (70)
Non-use incentives - No restriction on the consumption of efficient care (20,21) - Less optimistic and less justified compared to cost-sharing (74)
* High deductible health plans (HDHPS), **consumer-directed health plans (CDHPs), ***Value-based Insurance Design (VBID, ****GPs: general practitioners

Discussion

This systematic review study aimed to identifythe effects of demand-side interventions to control moral hazards in health systems. A variety of study objectives and methods were reviewed and reported in this study. The majority of studies investigated the effects of cost-sharing methods. The basis of cost-sharing goes back to the theory of moral hazards where nonparticipation in costs leads to reckless choices and increased costs (76). The study’s findings show that a variety of cost-sharing schemes exist—including uniform and fixed-rate cost-sharing, shift deductibles, high-level cost-sharing plans such as higher deductibles, high deductible health plans (HDHPS), consumer-directed health plans (CDHPS), and value-based cost-sharing or value-based insurance design (VBID)—which determines the cost-sharing rate based on the price elasticity of demand for health services. The bulk of the results related to cost-sharing showed a significant reduction in the consumption of health services; a few studies indicated no or little effect on consumption; this variation in results is expected in different studies due to the variety of regulatory cost-sharing rates in different countries. Regarding the reduction of service consumption, some essential points should be mentioned. The transitory effect is one of the significant issues in reducing the consumption of health services. In Kan and Suzuki’s study, the effect of reduction in demand for physician visits following the increase in coinsurance rate was not sustainable 6 months after the implementation of the program (36).The substitution effect is another significant effect of reducing service consumption. This effect shifts services with cost-sharing to free services or services with less cost-sharing (43,27,25). Since usually hospital services have lower cost-sharing because of less price elasticity, by shifting services from outpatient to inpatient, a reduction in the quality of services due to inpatient complications is excepted. It will also increase the total cost of health. These results are consistent with the results of a study by Yoo et al, where the increase in cost-sharing for outpatient services led to an increase in hospitalization and health costs (24). Fels in a model-based analysis showed that cost-sharing is a nonoptimal method because of the reduction of both essential and nonessential services (because of patients’ mistakes in distinguishing between essential and nonessentialservices) and reduction in access to health services (21). The results of this analysis are in line with the findings of the following studiesabout a reduction in the use of preventive care (45,47,54) reduction in medication adherence (45), and more sensitivity of low-income patients to cost-sharing for health care utilization (25,26,28). In this regard, value-based cost-sharing methods seek to eliminate the shortcomings, which also achieved positive results in this regard (56). From the financial dimension, the effect of cost-sharing included a small to a significant reduction in health care costs(12,32,36). Although the reduction of health costs is one of the most important positive findings of cost-sharing, the exposure to the following side effects in studies criticizes this achievement: shifting the financial burden to consumers (25), increasing the financial burden for consumers (16), and increasing health costs because of increased hospitalization (24). However, the results of empirical illustration showed that shift deductible plans reduce out-of-pocket payment costs(60). Moreover, in response to these shortcomings, value-based cost-sharing schemes were proposed as optimal methods (64-66).As a final point, increasing the profits of insurance organizations because of the reduction of insured claims is another positive and significant consequence of cost-sharing (16,61). Savings accounts are one of the means of financing and controlling consumer moral hazard and are also useful for future saving, which is implemented either compulsorily or voluntarily (18). Despite this function, the results of a study showed negative results in reducing health costs and reducing moral hazard in China, which the authors consider a result of the compulsory membership and social participation in the project,being less valuable compared with out-of-pocket payments.(67). Furthermore, the results of a study on the effect of health savings accounts on savings and the promotion of preventive behavior showed that the members of this plan do not perform both savings and preventive behavior at the same time (68). In addition, the results of another study showed that savings are reduced in voluntary schemes with generous employers (54). Generally, the results of studies on the consequences of savings accounts on the consumption of health services and costs were different, which were expected to be like this because of mandatory and voluntary membership and type of administration in different countries. The waiting list is an alternative to a user fee to reduce costs in countries with national health systems that control unnecessary demand by imposing the cost of time (14). The results of the included studies on the waiting list indicate that this intervention is not desirable from the perspective of patients(70) and is nonoptimal (19,70,72). The waiting list reduces health costs by potentially encouraging high-income patients or patients with high waiting costs to select a private setting (72). Although reducing the costs through the choices of private sectors by high-income people is considered an advantage, the result of the analysis by Olivella showed that the presence of the private sector reduces the willingness of public sector providers to reduce waiting time (71). Nonuse incentive schemes or bonus insurance often offers rewards in the form of a reduction in the next year’s premiums(13) or generous coverage for the next contract (20). These interventions aim to promote healthy behavior, prevent high-risk behaviors, and control demand from the source (74) without access restricting (21). The findings of the included studies showed positive findings in the direction of the goals of these programs. However, the public acceptance of these methods in a qualitative study showed less justifiability of these methods compared to cost-sharing methods (74).

Limitations of the Study

This study had some limitations. The first limitation was the methodological diversity of the studies and their heterogeneity therefore the narrative synthesis approach was used to summarize the results of the studies. The second limitation was the possibility of language bias due to the limitation of non-English articles on publishing or indexing the results and the focus of this study on Persian and English articles which led to the absence of studies in other languages in the analysis of results. Another limitation was that the majority of the studies concentrated on the impacts of cost-sharing, with fewer studies looking at the effects of other demand-side interventions. Finally, there was the possibility of researcher bias in favor of a specific intervention, which might have influenced the study’s outcomes.

Conclusion

Demand-side interventions were designed to reduce consumer motivation for unnecessary consumption. The results of this study showed that each of these interventions has advantages and disadvantages. The most important strengths of these interventions, in general, include reducing the consumption of health services, especially outpatient services, and reducing health costs and third-party payers’ costs. The downsides of these approaches include a reduction in service quality, a transfer in a financial burden to consumers, and limited access, particularly for low-income populations. When looking at the outcomes of interventions, it becomes clear that the majority of the benefits, particularly in cost-sharing and waiting list interventions, benefit insurance companies and third-party payers, while the drawbacks of these interventions disproportionately burden consumers. Therefore, in regulating these interventions in health systems and insurance organizations, it is necessary to pay more attention to these consequences and their management, as a lack of attention in this regard may impair the performance of insurance financial protection and health provision as one of the major goals of health systems.

Acknowledgment

This study was part of a PhD thesis in health services management supported by Iran University of Medical Sciences (grant No: IUMS/SHMIS-1399-3-37-19512.). The authors would like to thank all the staff involved in the School of Health Management and Information Sciences and the research department of Iran University of medical sciences.

Ethical Approval

The study was approved by the local ethical committee of Iran University of Medical Sciences (code: IR.IUMS.REC.1399.1103).

Conflict of Interests

The authors declare that they have no competing interests.
Appendix 1

Search strategy

Databases Search strategy
PubMed (“moral hazard”[tiab] OR “moral hazards”[tiab] OR “principal agency problem”[tiab] OR “principal agent dilemma”[tiab] OR “principal agent problem”[tiab] OR “unnecessary use”[tiab] OR “unnecessary utilization”[tiab] OR “non-essential use”[tiab] OR “non essential utilization”[tiab] OR overutilization[tiab] OR overutilizations[tiab] OR overutilization[tiab] OR overutilisations[tiab] OR “over-utilization”[tiab] OR “over-utilizations”[tiab] OR “over-utilisation”[tiab] OR “over-utilisations”[tiab]) AND (“Delivery of Healthcare”[tiab] OR “Healthcare Deliveries”[tiab] OR “Healthcare Delivery”[tiab] OR (Deliveries[tiab] AND Healthcare[tiab]) OR (Delivery[tiab] AND Healthcare[tiab]) OR “Health Care Delivery”[tiab] OR (Delivery[tiab] AND “Health Care”[tiab]) OR “Health Care”[tiab] OR (Care[tiab] AND Health[tiab]) OR Healthcare[tiab] OR “Health Care Systems”[tiab] OR “Health Care System”[tiab] OR (System[tiab] AND “Health Care”[tiab]) OR (Systems[tiab] AND “Health Care”[tiab]) OR “Healthcare Systems”[tiab] OR “Healthcare System”[tiab] OR (System[tiab] AND Healthcare[tiab]) OR (Systems[tiab] AND Healthcare[tiab]) OR “Community-Based Distribution”[tiab] OR “Community Based Distribution”[tiab] OR “Community-Based Distributions”[tiab] OR (Distribution[tiab] AND “Community-Based”[tiab]) OR (Distributions[tiab] AND “Community-Based”[tiab]) OR “health system”[tiab] OR “long stay care”[tiab] OR “long term care”[tiab] OR “health insurance”[tiab] OR “health service”[tiab] OR “health services”[tiab] OR “medical care“[tiab] OR “medical service”[tiab] OR “medical services”[tiab] OR drug[tiab] OR medication[tiab] OR outpatient[tiab] OR “physician visit”[tiab] OR “outpatient visit”[tiab] OR inpatient[tiab] OR hospitalization[tiab] OR hospitalization[tiab] OR “hospital admission”[tiab] OR “hospital care”[tiab])
Embase(“moral hazard”:ti,ab OR “moral hazards”:ti,ab OR “principal agency problem”:ti,ab OR “principal agent dilemma”:ti,ab OR “principal agent problem”:ti,ab OR “unnecessary use”:ti,ab OR “unnecessary utilization”:ti,ab OR “non-essential use”:ti,ab OR “non essential utilization”:ti,ab OR overutilization:ti,ab OR overutilizations:ti,ab OR overutilization:ti,ab OR overutilisations:ti,ab OR “over-utilization”:ti,ab OR “over-utilizations”:ti,ab OR “over-utilisation”:ti,ab OR “over-utilisations”:ti,ab) AND (“Delivery of Healthcare”:ti,ab OR “Healthcare Deliveries”:ti,ab OR “Healthcare Delivery”:ti,ab OR (Deliveries:ti,ab AND Healthcare:ti,ab) OR (Delivery:ti,ab AND Healthcare:ti,ab) OR “Health Care Delivery”:ti,ab OR (Delivery:ti,ab AND “Health Care”:ti,ab) OR “Health Care”:ti,ab OR (Care:ti,ab AND Health:ti,ab) OR Healthcare:ti,ab OR “Health Care Systems”:ti,ab OR “Health Care System”:ti,ab OR (System:ti,ab AND “Health Care”:ti,ab) OR (Systems:ti,ab AND “Health Care”:ti,ab) OR “Healthcare Systems”:ti,ab OR “Healthcare System”:ti,ab OR (System:ti,ab AND Healthcare:ti,ab) OR (Systems:ti,ab AND Healthcare:ti,ab) OR “Community-Based Distribution”:ti,ab OR “Community Based Distribution”:ti,ab OR “Community-Based Distributions”:ti,ab OR (Distribution:ti,ab AND “Community-Based”:ti,ab) OR (Distributions:ti,ab AND “Community-Based”:ti,ab) OR “health system”:ti,ab OR “long stay care”:ti,ab OR “long term care”:ti,ab OR “health insurance”:ti,ab OR “health service”:ti,ab OR “health services”:ti,ab OR “medical care“:ti,ab OR “medical service”:ti,ab OR “medical services”:ti,ab OR drug:ti,ab OR medication:ti,ab OR outpatient:ti,ab OR “physician visit”:ti,ab OR “outpatient visit”:ti,ab OR inpatient:ti,ab OR hospitalization:ti,ab OR hospitalization:ti,ab OR “hospital admission”:ti,ab OR “hospital care”:ti,ab)
Scopus(TITLE-ABS-KEY(“moral hazard”) OR TITLE-ABS-KEY(“moral hazards”) OR TITLE-ABS-KEY(“principal agency problem”) OR TITLE-ABS-KEY(“principal agent dilemma”) OR TITLE-ABS-KEY(“principal agent problem”) OR TITLE-ABS-KEY(“unnecessary use”) OR TITLE-ABS-KEY(“unnecessary utilization”) OR TITLE-ABS-KEY(“non-essential use”) OR TITLE-ABS-KEY(“non essential utilization”) OR TITLE-ABS-KEY(overutilization) OR TITLE-ABS-KEY(overutilizations) OR TITLE-ABS-KEY(overutilization) OR TITLE-ABS-KEY(overutilisations) OR TITLE-ABS-KEY(“over-utilization”) OR TITLE-ABS-KEY(“over-utilizations”) OR TITLE-ABS-KEY(“over-utilisation”) OR TITLE-ABS-KEY(“over-utilisations”)) AND (TITLE-ABS-KEY(“Delivery of Healthcare”) OR TITLE-ABS-KEY(“Healthcare Deliveries”) OR TITLE-ABS-KEY(“Healthcare Delivery”) OR (TITLE-ABS-KEY(Deliveries) AND TITLE-ABS-KEY(Healthcare)) OR (TITLE-ABS-KEY(Delivery) AND TITLE-ABS-KEY(Healthcare)) OR TITLE-ABS-KEY(“Health Care Delivery”) OR (TITLE-ABS-KEY(Delivery) AND TITLE-ABS-KEY(“Health Care”)) OR TITLE-ABS-KEY(“Health Care”) OR (TITLE-ABS-KEY(Care) AND TITLE-ABS-KEY(Health)) OR TITLE-ABS-KEY(Healthcare) OR TITLE-ABS-KEY(“Health Care Systems”) OR TITLE-ABS-KEY(“Health Care System”) OR (TITLE-ABS-KEY(System) AND TITLE-ABS-KEY(“Health Care”)) OR (TITLE-ABS-KEY(Systems) AND TITLE-ABS-KEY(“Health Care”)) OR TITLE-ABS-KEY(“Healthcare Systems”) OR TITLE-ABS-KEY(“Healthcare System”) OR (TITLE-ABS-KEY(System) AND TITLE-ABS-KEY(Healthcare)) OR (TITLE-ABS-KEY(Systems) AND TITLE-ABS-KEY(Healthcare)) OR TITLE-ABS-KEY(“Community-Based Distribution”) OR TITLE-ABS-KEY(“Community Based Distribution”) OR TITLE-ABS-KEY(“Community-Based Distributions”) OR (TITLE-ABS-KEY(Distribution) AND TITLE-ABS-KEY(“Community-Based”)) OR (TITLE-ABS-KEY(Distributions) AND TITLE-ABS-KEY(“Community-Based”)) OR TITLE-ABS-KEY(“health system”) OR TITLE-ABS-KEY(“long stay care”) OR TITLE-ABS-KEY(“long term care”) OR TITLE-ABS-KEY(“health insurance”) OR TITLE-ABS-KEY(“health service”) OR TITLE-ABS-KEY(“health services”) OR TITLE-ABS-KEY(“medical care“) OR TITLE-ABS-KEY(“medical service”) OR TITLE-ABS-KEY(“medical services”) OR TITLE-ABS-KEY(drug) OR TITLE-ABS-KEY(medication) OR TITLE-ABS-KEY(outpatient) OR TITLE-ABS-KEY(“physician visit”) OR TITLE-ABS-KEY(“outpatient visit”) OR TITLE-ABS-KEY(inpatient) OR TITLE-ABS-KEY(hospitalization) OR TITLE-ABS-KEY(hospitalization) OR TITLE-ABS-KEY(“hospital admission”) OR TITLE-ABS-KEY(“hospital care”))
Web of Science(TS=(“moral hazard”) OR TS=(“moral hazards”) OR TS=(“principal agency problem”) OR TS=(“principal agent dilemma”) OR TS=(“principal agent problem”) OR TS=(“unnecessary use”) OR TS=(“unnecessary utilization”) OR TS=(“non-essential use”) OR TS=(“non essential utilization”) OR TS=(overutilization) OR TS=(overutilizations) OR TS=(overutilization) OR TS=(overutilisations) OR TS=(“over-utilization”) OR TS=(“over-utilizations”) OR TS=(“over-utilisation”) OR TS=(“over-utilisations”)) AND (TS=(“Delivery of Healthcare”) OR TS=(“Healthcare Deliveries”) OR TS=(“Healthcare Delivery”) OR (TS=(Deliveries) AND TS=(Healthcare)) OR (TS=(Delivery) AND TS=(Healthcare)) OR TS=(“Health Care Delivery”) OR (TS=(Delivery) AND TS=(“Health Care”)) OR TS=(“Health Care”) OR (TS=(Care) AND TS=(Health)) OR TS=(Healthcare) OR TS=(“Health Care Systems”) OR TS=(“Health Care System”) OR (TS=(System) AND TS=(“Health Care”)) OR (TS=(Systems) AND TS=(“Health Care”)) OR TS=(“Healthcare Systems”) OR TS=(“Healthcare System”) OR (TS=(System) AND TS=(Healthcare)) OR (TS=(Systems) AND TS=(Healthcare)) OR TS=(“Community-Based Distribution”) OR TS=(“Community Based Distribution”) OR TS=(“Community-Based Distributions”) OR (TS=(Distribution) AND TS=(“Community-Based”)) OR (TS=(Distributions) AND TS=(“Community-Based”)) OR TS=(“health system”) OR TS=(“long stay care”) OR TS=(“long term care”) OR TS=(“health insurance”) OR TS=(“health service”) OR TS=(“health services”) OR TS=(“medical care“) OR TS=(“medical service”) OR TS=(“medical services”) OR TS=(drug) OR TS=(medication) OR TS=(outpatient) OR TS=(“physician visit”) OR TS=(“outpatient visit”) OR TS=(inpatient) OR TS=(hospitalization) OR TS=(hospitalization) OR TS=(“hospital admission”) OR TS=(“hospital care”))
ProQuest TI,AB,SU(“moral hazard” OR “moral hazards” OR “principal agency problem” OR “principal agent dilemma” OR “principal agent problem” OR “unnecessary use” OR “unnecessary utilization” OR “non-essential use” OR “non essential utilization” OR overutilization OR overutilizations OR overutilization OR overutilisations OR “over-utilization” OR “over-utilizations” OR “over-utilisation” OR “over-utilisations”) AND TI,AB,SU(“Delivery of Healthcare” OR “Healthcare Deliveries” OR “Healthcare Delivery” OR (Deliveries AND Healthcare) OR (Delivery AND Healthcare) OR “Health Care Delivery” OR (Delivery AND “Health Care”) OR “Health Care” OR (Care AND Health) OR Healthcare OR “Health Care Systems” OR “Health Care System” OR (System AND “Health Care”) OR (Systems AND “Health Care”) OR “Healthcare Systems” OR “Healthcare System” OR (System AND Healthcare) OR (Systems AND Healthcare) OR “Community-Based Distribution” OR “Community Based Distribution” OR “Community-Based Distributions” OR (Distribution AND “Community-Based”) OR (Distributions AND “Community-Based”) OR “health system” OR “long stay care” OR “long term care” OR “health insurance” OR “health service” OR “health services” OR “medical care“ OR “medical service” OR “medical services” OR drug OR medication OR outpatient OR “physician visit” OR “outpatient visit” OR inpatient OR hospitalization OR hospitalization OR “hospital admission” OR “hospital care”)
Appendix 2

The general characteristics of the included studies

Author/year /source Country/ languageApproach &DesignDemand side interventionAnalyzed outcomeQuality appraisal score (out of 10)
Abdus S. 2020(47) USA/ EnglishQuantitative: Cross sectionalHigh‐deductible health plan (HDHPs), consumer‐directed health plans (CDHPs), low‐deductible health plans (LDHPs), no‐deductible health plans (NDHPs). health care utilization:ambulatory visit, specialist visit, preventive services 10
Alessie RJM, et al 2020 (5) Netherlands /EnglishQuantitative: longitudinal Internet Studies voluntary deductiblewith premium reduction/ rebate moral hazard (GP visits, medical specialist visits, number of days spent in a hospital, number of visits to mental health care9
Agarwal R, et al 2017(45) USA/ Englishsystematic reviewhigh-deductible health plans (HDHPs)health care utilization and health care costs9
Bakx P et al 2015 (44) Germany, Belgium, Switzerland, NetherlandsComparative studyCost sharing: Copayments& deductibles -Managed competition: Financial risk and risk adjustment Effect on accessEffect on efficiency 8
Bardey D & Lesur R. 2005 (43) France/ Englishtheoretical approach based on model formulationDeductibleOptimal health insurance contract6
Beeuwkes Buntin M, et al 2011 (54) USA/ EnglishQuantitative: Retrospective difference-in difference high deductible health plans (HDHPs) & consumer directedhealth plans (CDHPs) Healthcare spending and use of recommendedpreventive care 8
Benjiang M, et al. 2021 (20) China / Englishtheoretical approach based on model formulationNo-claim Bonus and Coverage Upper Boundrisk-reducing effort and utility8
Cattel D, et al. 2017 (57) Netherlands/ English Quantitative: developing a simulationmodel different deductiblemodalities: first-euro deductible and doughnut hole deductible cost containment incentives(CCI) 7
Chen T. 2021 (67) China/ EnglishQuantitative: Empirically designhealth savings accounts (HSAs) medical expenses and moralhazard 8
Chernew ME, et al 2000 (64) USA/ Englishtheoretical approach based on model formulationoptimal cost sharing provisions /Treatment-specific copaymentsoptimal insurance contracts7
Choi Y, et al. 2015 (29) Korean/ EnglishQuantitative: panel surveyIntroduction cost sharing in private health insurance (PHIoutpatient visits, inpatient visits, length of stay in hospital9
Cockx & Brasseur C. 2003 (27) Belgium/ EnglishQuantitative: natural experiment /differences-in differences (DD) estimator To increase copayment rates ofthree types of physician services (GPs) visits, home visits, specialist visits and efficiency8
Drevs F & Tscheulin.d k. 2013 (58) Germany/English Quantitative: Two experimental studiesco-payment with a rebate frame -co-payment with a premium reduction frameex-post moral hazard9
Ebrahimnia M, et al 2014 (9) Iran/ PersianQuantitative: Cross sectionalcoinsurance Outpatient servicesInpatient services and medication 8
Fan M et al 2016 (69) ChinaEnglish Quantitative: a quasi-natural experiment/ DIDreduced MSA fundshealth-care expenditures10
Felder S2008 (19) Germany/ Englishtheoretical approach based on model formulation queuing as a rationing devicewaiting time and coinsurance Optimal insurance contracts8
Fels M Health. 2020 (21) Germany/ Englishtheoretical approach based on model formulation cost sharing andbonus payments/ rebates insurance access to efficient care8
Ferguson W, et al. 2020 (59) USA/ EnglishReview article Consumer-Driven Health Plans/Consumer engagement/three-tier payment system financial savings & transparency of healthcare cost.6
Fiorio CV& Siciliani L 2010 (32) Italy/ English Quantitative:natural experiment/difference-in-difference To Increase copayment per capita number ofprescriptionsper capita public pharmaceutical expenditure 9
Frank MB, et al. 2012 (56) USA/ English Quantitative:econometricmodel with a difference-in-difference design Value-based Insurance DesignCopayments on VBID brand statins medication adherence (medication possession)9
Gerfin M & Schellhorn M. 2006 (38) Switzerland/English Quantitative:Cross- sectional Different size of deductiblesthe probability of going to the doctor8
Gravelle H& Siciliani L 2008 (70) United Kingdom / Englishtheoretical approach based on model formulationwaiting timeOptimal quality8
Hafner P& Mahlich JC. 2015 (28) Austria/ English Quantitative:survey data hypothetical co-payments in the range of €5 to €200average annual numbers of physician’s office visits9
Herr A & Suppliet M 2017 (63) Germany/ English Quantitative:econometricmodel with a difference-in-difference design price-related co-payment tiers/exempt from co-payments Decreasing drug prices and demand8
Hoel M& Sæther EM 2003 (72) NorwayEnglish theoretical approach based on model formulationwaiting timecost of public health7
Huber CA, et al 2012 (26) Germany, Switzerland,English Quantitative:cross-sectional introduction of (additional) cost-sharingvisits to a general practitioner or a specialist during the past 12 months& socio-demographic factors9
Jakobsson N & Svensson M. 2016 (39) Sweden/ English Quantitative:panel data model variation of copayments per primary care physician visitthe number of visits per capita per year9
Jakobsson N & Svensson M. 2016 (40) Sweden/ English Quantitative:quasi-experimental approaches price reform/ co-payments in a tax-financed health-care systemnumber of daily visits, socio-economic/demographic9
Kan M & Suzuki W 2010 (36) Japan/ English Quantitative:natural experiment cost sharing: increase in the coinsurance rate Number of physician visits& expenditure per visit 9
Kiil A & Houlberg K. 2014(25) Denmark/ EnglishReview articlecopayment demand effects: prescription medicine, consultationswith general practitioners and specialists, ambulatorycare and, prevalence of hospitalization 9
Kim J et al 2005 (46) South Korea/ English Quantitative:Observational continuous survey performed every 3 years To increase cost sharingdemand for physician service and price elasticities9
Koc C 2011 (65) USA/ English Quantitative:GeneralizedMethod of Moments(GMM) differential cost sharing based on disease statusoptimal insurance for physician services9
Kullgren JT 2013 (49) USA/ English Quantitative:Cross-sectional analysis of nationally-representative data high-deductible health plan (HDHP)Self-reported smoking status9
Landsem MM & Magnussen J. 2018 (31) Norway/ English Quantitative:experimentaldesign introduction of a co-payment total utilization of the GPs serviceand this effect varies across different patient groups 10
Law CK& Yip PS. 2002 (35) Hong Kong/ English Quantitative:Retrospective study (scenario user-fee policynon-emergency attendances in Hong Kong9
Law MR, et al 2017 (52) Canada/ English Quantitative:quasi-experimental The income-based deductibleDrug and health care utilization and cost among older adults.9
Lin H, Sacks DW. 2019 (55) USA/ English Quantitative:Econometric approach nonlinear cost-sharing( high deductible health planhealth care demand10
Mirian I et al 2020 (16) Iran/English review articleDeductibleImpacts on utilization of the insured -Financial impacts on the insured-Financial impacts on health insurance organization8
Mortensen K 2010 (42) USA/ English Quantitative:Quasi experimental,(difference-in-differences) Copaymentsnonemergency visits in emergency departments9
Olivella P 2003 (71) SpainEnglish theoretical approach based on model formulationWaiting lists the public health administration’s (PbHA’s) decisions on waiting lists for public treatments.incentives to reduce waiting lists7
Pauly MV& Blavin FE 2008 (66) USA/ Englishtheoretical approach based on model formulationValue based cost sharingOptimal insurance6
Petrou P 2015 (33) Cyprus/ English Quantitative:interrupted time-series (ITS) analysis introduction of co-payment fee of EUR10Emergency room services9
Ponzo M& Scoppa 2021 (53) Italy/English Quantitative:experimentaldesign exemption from cost-sharingdemand for specialist visits, diagnostic checks and drug consumption10
Pütz C& Hagist C 2006 (61) Germany/ EnglishQuantitative: trial schemebonus of €240 per year plus to pay a deductible for their medical treatment of up to €300. - the principles of solidarity;-insurance claims 8
Rabin et al 2020 (48) USA/ English Quantitative:cross- sectional survey Deductiblesincreased in employer- provided insurance, combine HRAs with HDHPs. medical debt,deferred needed care 10
Reddy SR, et al (2014) (50) USA/ English Quantitative:pre-post with comparison group study design High-Deductible Health Plan (HDHP) Outpatient Visits and Associated Diagnostic Tests:laboratory and radiology tests 8
Sabik LM & Gandhi SO. 2016 (34) USA/ English Quantitative:Quasi experimental design changes in Medicaid ED copayment policies (increase copayment)Non urgent Emergency department ED utilization among nonelderly adult enrollees8
Schellhorn M. (2001) (51) Swiss/ EnglishQuantitative: A generalized method of moments (GMM) estimator introduction of a choice ofdeductiblefor health services in the mandatory basic health insurance Physician service utilization.8
Schreyogg J& Grabka MM 2010 (41) Germany/English Quantitative:natural experimentdifference-in-differenceapproach introduction copayment for ambulatory care in 2004 for individuals with statutory health insuranceoverall demand for physician visits10
Schubert S. 2014 (12) Germany/English Quantitative:numerical analysis/GEM mandatory deductibles and further elevating copayments health care demand andhealth care expenditure 7
Serna N. 2021 (37) USA/ English Quantitative:experimentaldesign tier coinsurance and income base copaysutilization of health services10
Steinorth P J 2011 (68) Germany/ Englishtheoretical approach based on model formulationhealth savings accounts with tax subsidy optimal savings,insurance demand and prevention effort over the course of a lifetime 8
Thönnes S 2019 (73) Germany/English Quantitative: panel datapremium refundsdifferent measures of medical demand10
Trottmann M, et al 2012 (30) Switzerland/English Quantitative: panel datasetSupply-side cost sharing and demand-side cost sharing (through voluntary deductibles)use of medical services10
Ullrich CG 2002 (74) Germany/ English qualitative guided interviewscost-sharing and risk premiumssocial acceptance of cost-sharing and risk premiums by members of the German statutory health insurance.8
van Kleef RC, et al 2009 (60) Netherlands/ English Quantitative:empirical illustration Shifted Deductibles moral hazard &out-of-pocket expenditures 9
van Winssen KP2015 (62) Netherlands/ English Quantitative:empiricalStatistical analyses voluntary deductible (VD) in return for a premium rebate.financial profitability9
Yaping Wu, et al 2021 (75) China/ Englishtheoretical approach based on model formulationPatient incentive (risk premium ) versus provider incentivePhysician-patient collusion and health costs8
Winkelmann R 2004(23) Germany/ English Quantitative:natural experiment/ differences-in-differences estimates To increase co-payments for prescription drugs price sensitivity of demandfor physicians’ services 9
Yoo KB, et al 2016 (24) Korea/ English gtime series study/ statistic regression analysisintroduction of out- patient co-payment scheme.medical cost, out patients and inpatients visits9
Zhang H & Yuen P 2016 (18) China/ English Quantitative:Econometric model Medical Savings Account balance outpatient utilization 10
  54 in total

1.  Optimal health insurance: the case of observable, severe illness.

Authors:  M E Chernew; W E Encinosa; R A Hirth
Journal:  J Health Econ       Date:  2000-09       Impact factor: 3.883

2.  Copayments did not reduce medicaid enrollees' nonemergency use of emergency departments.

Authors:  Karoline Mortensen
Journal:  Health Aff (Millwood)       Date:  2010-09       Impact factor: 6.301

3.  Nonparametric bounds on the effect of deductibles in health care insurance on doctor visits - Swiss evidence.

Authors:  Michael Gerfin; Martin Schellhorn
Journal:  Health Econ       Date:  2006-09       Impact factor: 3.046

4.  Impact of co-payment for outpatient utilization among Medical Aid beneficiaries in Korea: A 5-year time series study.

Authors:  Ki-Bong Yoo; Hong-Uk Ahn; Eun-Cheol Park; Tae Hyun Kim; Sun Jung Kim; Jeoung A Kwon; Sang Gyu Lee
Journal:  Health Policy       Date:  2016-07-12       Impact factor: 2.980

5.  Incentivizing efficient utilization without reducing access: The case against cost-sharing in insurance.

Authors:  Markus Fels
Journal:  Health Econ       Date:  2020-04-22       Impact factor: 3.046

6.  A method to simulate incentives for cost containment under various cost sharing designs: an application to a first-euro deductible and a doughnut hole.

Authors:  D Cattel; R C van Kleef; R C J A van Vliet
Journal:  Eur J Health Econ       Date:  2016-11-14

7.  Acute care service utilisation and the possible impacts of a user-fee policy in Hong Kong.

Authors:  C K Law; P S F Yip
Journal:  Hong Kong Med J       Date:  2002-10       Impact factor: 2.227

8.  Demand-side strategies to deal with moral hazard in public insurance for long-term care.

Authors:  Pieter Bakx; Dov Chernichovsky; Francesco Paolucci; Erik Schokkaert; Maria Trottmann; Juergen Wasem; Frederik Schut
Journal:  J Health Serv Res Policy       Date:  2015-03-12

9.  Conducting a critical interpretive synthesis of the literature on access to healthcare by vulnerable groups.

Authors:  Mary Dixon-Woods; Debbie Cavers; Shona Agarwal; Ellen Annandale; Antony Arthur; Janet Harvey; Ron Hsu; Savita Katbamna; Richard Olsen; Lucy Smith; Richard Riley; Alex J Sutton
Journal:  BMC Med Res Methodol       Date:  2006-07-26       Impact factor: 4.615

10.  The role of national health insurance for achieving UHC in the Philippines: a mixed methods analysis.

Authors:  Konrad Obermann; Matthew Jowett; Soonman Kwon
Journal:  Glob Health Action       Date:  2018       Impact factor: 2.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.